Literature DB >> 23042148

Antiphospholipid antibody syndrome.

Paul Yang1, Jonathan N Kruh, C Stephen Foster.   

Abstract

PURPOSE OF REVIEW: Antiphospholipid syndrome is a rare cause of ocular vaso-occlusive disease, but is associated with significant systemic morbidity and mortality. Thus, early diagnosis and treatment is essential. RECENT
FINDINGS: Although the pathophysiology of antiphospholipid syndrome continues to be poorly understood, there has been continued progress with regard to the relationship between antiphospholipid antibody and its target, β-2-glycoprotein I. Due to numerous limitations with standard serologic evaluation, new approaches to the evaluation of patient serum are being considered. New guidelines for the treatment and management of antiphospholipid antibody syndrome have been established by the 13th International Committee on Antiphospholipid Antibodies.
SUMMARY: A better understanding of the pathophysiology behind antiphospholipid antibody syndrome has led to novel approaches in the diagnosis and treatment of this disease.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23042148     DOI: 10.1097/ICU.0b013e328358b937

Source DB:  PubMed          Journal:  Curr Opin Ophthalmol        ISSN: 1040-8738            Impact factor:   3.761


  3 in total

1.  Diagnostic ramifications of ocular vascular occlusion as a first thrombotic event associated with factor V Leiden and prothrombin gene heterozygosity.

Authors:  Samantha Schockman; Charles J Glueck; Robert K Hutchins; Jaykumar Patel; Parth Shah; Ping Wang
Journal:  Clin Ophthalmol       Date:  2015-04-03

Review 2.  Current concepts in the diagnosis and management of antiphospholipid syndrome and ocular manifestations.

Authors:  Gunay Uludag; Neil Onghanseng; Anh N T Tran; Muhammad Hassan; Muhammad Sohail Halim; Yasir J Sepah; Diana V Do; Quan Dong Nguyen
Journal:  J Ophthalmic Inflamm Infect       Date:  2021-04-09

3.  Clinical and serological features of patients referred through a rheumatology triage system because of positive antinuclear antibodies.

Authors:  Christie Fitch-Rogalsky; Whitney Steber; Michael Mahler; Terri Lupton; Liam Martin; Susan G Barr; Dianne P Mosher; James Wick; Marvin J Fritzler
Journal:  PLoS One       Date:  2014-04-04       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.